Cardiol Therapeutics Inc.
CRDLNasdaq
$1.21
↓ -1.6%Jul 17 close · end-of-day
Price
1Y↓ -6.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Cardiol Therapeutics Inc. focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD) Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability.
- CEO
- David G. Elsley
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Ontario
- Website
- cardiolrx.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.